Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst ...

Sales of Novo Nordisk’s diabetes drugs including Ozempic slowed to grow at 8 per cent year on year in the first half, down sharply from its rate last year, as the company loses market share to rival ...

Danish pharma giant Novo Nordisk reports 32% rise in Q2 net profit to $4.1B, driven by strong sales of Ozempic and Wegovy ...